Meralgia paresthetica: Relation to obesity, advanced age, and diabetes mellitus

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Objective: To determine the incidence of meralgia paresthetica (MP) and its relationship to diabetes mellitus (DM) and obesity. Methods: A population-based study was performed within Olmstead County Minnesota, from January 1, 1990, to December 31, 1999. MP incidence and its association with age, gender, body mass index (BMI), and DM were reviewed. Results: A total of 262 patients with MP, 262 normal controls, and 262 BMI-matched normal controls with mean age of 50 years were identified (51% men). The age- and sex-adjusted incidence of MP was 32.6 per 100,000 patient years, whereas the incidence of MP in people with DM was 247 per 100,000 patient years, 7 times the occurrence of MP in the general population. Of the patients with MP, 28% had DM vs 17% of BMI-matched controls and the majority of people with MP developed DM after the diagnosis of MP. Patients with MP are 2 times more likely to develop DM (odds ratio 2, 95% confidence interval 1.3-3.0, p = 0.0027). The mean BMI of patients with MP (30.1 kg/m2, obese class I) was significantly higher than that of age- and gendermatched controls (27.3 kg/m 2, overweight). MP incidence increased 12.9 per 100,000 patient years in the hemidecade study period with an associated increase in both BMI (2.2 kg/m 2) and average age (3 years). Conclusions: MP is a frequent painful neuropathy associated with obesity, advancing age, and DM. The incidence rate of MP is predicted to increase as these demographics increase in world populations. Because MP associates with DM beyond weight- and age-matched controls, more aggressive counseling of these patients in prevention ofDMmay be warranted.

Original languageEnglish (US)
Pages (from-to)1538-1542
Number of pages5
JournalNeurology
Volume77
Issue number16
DOIs
StatePublished - Oct 18 2011

Fingerprint

Diabetes Mellitus
Obesity
Body Mass Index
Incidence
Meralgia paresthetica
Population
Counseling
Odds Ratio
Demography
Confidence Intervals
Weights and Measures

ASJC Scopus subject areas

  • Clinical Neurology
  • Arts and Humanities (miscellaneous)

Cite this

Meralgia paresthetica : Relation to obesity, advanced age, and diabetes mellitus. / Parisi, Thomas J.; Mandrekar, Jayawant; Dyck, P. James B; Klein, Christopher Jon.

In: Neurology, Vol. 77, No. 16, 18.10.2011, p. 1538-1542.

Research output: Contribution to journalArticle

@article{0005deeb875b433b86b0f61700cb1726,
title = "Meralgia paresthetica: Relation to obesity, advanced age, and diabetes mellitus",
abstract = "Objective: To determine the incidence of meralgia paresthetica (MP) and its relationship to diabetes mellitus (DM) and obesity. Methods: A population-based study was performed within Olmstead County Minnesota, from January 1, 1990, to December 31, 1999. MP incidence and its association with age, gender, body mass index (BMI), and DM were reviewed. Results: A total of 262 patients with MP, 262 normal controls, and 262 BMI-matched normal controls with mean age of 50 years were identified (51{\%} men). The age- and sex-adjusted incidence of MP was 32.6 per 100,000 patient years, whereas the incidence of MP in people with DM was 247 per 100,000 patient years, 7 times the occurrence of MP in the general population. Of the patients with MP, 28{\%} had DM vs 17{\%} of BMI-matched controls and the majority of people with MP developed DM after the diagnosis of MP. Patients with MP are 2 times more likely to develop DM (odds ratio 2, 95{\%} confidence interval 1.3-3.0, p = 0.0027). The mean BMI of patients with MP (30.1 kg/m2, obese class I) was significantly higher than that of age- and gendermatched controls (27.3 kg/m 2, overweight). MP incidence increased 12.9 per 100,000 patient years in the hemidecade study period with an associated increase in both BMI (2.2 kg/m 2) and average age (3 years). Conclusions: MP is a frequent painful neuropathy associated with obesity, advancing age, and DM. The incidence rate of MP is predicted to increase as these demographics increase in world populations. Because MP associates with DM beyond weight- and age-matched controls, more aggressive counseling of these patients in prevention ofDMmay be warranted.",
author = "Parisi, {Thomas J.} and Jayawant Mandrekar and Dyck, {P. James B} and Klein, {Christopher Jon}",
year = "2011",
month = "10",
day = "18",
doi = "10.1212/WNL.0b013e318233b356",
language = "English (US)",
volume = "77",
pages = "1538--1542",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "16",

}

TY - JOUR

T1 - Meralgia paresthetica

T2 - Relation to obesity, advanced age, and diabetes mellitus

AU - Parisi, Thomas J.

AU - Mandrekar, Jayawant

AU - Dyck, P. James B

AU - Klein, Christopher Jon

PY - 2011/10/18

Y1 - 2011/10/18

N2 - Objective: To determine the incidence of meralgia paresthetica (MP) and its relationship to diabetes mellitus (DM) and obesity. Methods: A population-based study was performed within Olmstead County Minnesota, from January 1, 1990, to December 31, 1999. MP incidence and its association with age, gender, body mass index (BMI), and DM were reviewed. Results: A total of 262 patients with MP, 262 normal controls, and 262 BMI-matched normal controls with mean age of 50 years were identified (51% men). The age- and sex-adjusted incidence of MP was 32.6 per 100,000 patient years, whereas the incidence of MP in people with DM was 247 per 100,000 patient years, 7 times the occurrence of MP in the general population. Of the patients with MP, 28% had DM vs 17% of BMI-matched controls and the majority of people with MP developed DM after the diagnosis of MP. Patients with MP are 2 times more likely to develop DM (odds ratio 2, 95% confidence interval 1.3-3.0, p = 0.0027). The mean BMI of patients with MP (30.1 kg/m2, obese class I) was significantly higher than that of age- and gendermatched controls (27.3 kg/m 2, overweight). MP incidence increased 12.9 per 100,000 patient years in the hemidecade study period with an associated increase in both BMI (2.2 kg/m 2) and average age (3 years). Conclusions: MP is a frequent painful neuropathy associated with obesity, advancing age, and DM. The incidence rate of MP is predicted to increase as these demographics increase in world populations. Because MP associates with DM beyond weight- and age-matched controls, more aggressive counseling of these patients in prevention ofDMmay be warranted.

AB - Objective: To determine the incidence of meralgia paresthetica (MP) and its relationship to diabetes mellitus (DM) and obesity. Methods: A population-based study was performed within Olmstead County Minnesota, from January 1, 1990, to December 31, 1999. MP incidence and its association with age, gender, body mass index (BMI), and DM were reviewed. Results: A total of 262 patients with MP, 262 normal controls, and 262 BMI-matched normal controls with mean age of 50 years were identified (51% men). The age- and sex-adjusted incidence of MP was 32.6 per 100,000 patient years, whereas the incidence of MP in people with DM was 247 per 100,000 patient years, 7 times the occurrence of MP in the general population. Of the patients with MP, 28% had DM vs 17% of BMI-matched controls and the majority of people with MP developed DM after the diagnosis of MP. Patients with MP are 2 times more likely to develop DM (odds ratio 2, 95% confidence interval 1.3-3.0, p = 0.0027). The mean BMI of patients with MP (30.1 kg/m2, obese class I) was significantly higher than that of age- and gendermatched controls (27.3 kg/m 2, overweight). MP incidence increased 12.9 per 100,000 patient years in the hemidecade study period with an associated increase in both BMI (2.2 kg/m 2) and average age (3 years). Conclusions: MP is a frequent painful neuropathy associated with obesity, advancing age, and DM. The incidence rate of MP is predicted to increase as these demographics increase in world populations. Because MP associates with DM beyond weight- and age-matched controls, more aggressive counseling of these patients in prevention ofDMmay be warranted.

UR - http://www.scopus.com/inward/record.url?scp=82955167986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82955167986&partnerID=8YFLogxK

U2 - 10.1212/WNL.0b013e318233b356

DO - 10.1212/WNL.0b013e318233b356

M3 - Article

C2 - 21975198

AN - SCOPUS:82955167986

VL - 77

SP - 1538

EP - 1542

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 16

ER -